AKCA

Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (NASDAQ:RNA), as an independent member of its Board of Directors. Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum's board. Ms. Boyce has extensive expertise in global pharmaceut

NEW YORK, Sept. 26, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating: Akcea Therapeutics, Inc. (NASDAQ: AKCA) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Ionis Pharmaceuticals, Inc. Under the terms of the agreement, Ionis will acquire all of the outstanding shares of Akcea common stock it does not already own, approximately 24%, for $18.15 per share in cash. Visit our website to learn more about your legal rights and options: https://halpersadeh.com/actions/akcea-therapeutics-inc-akca-stock-merger-ionis/. Builders FirstSource, Inc. (NASDAQ: BLDR) concerning potential v

NEW YORK, Sept. 25, 2020 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq.WeissLaw LLP1500 Broadway, 16th FloorNew York, NY  10036(212) 682-3025(888) 593-4771[email protected] Akcea Therapeutics, Inc. (NASDAQ: AKCA) WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Akcea Therapeutics, Inc. (NASDAQ: AKCA) in connection with the proposed acquisition of the company by Ionis Pharmaceuticals, Inc. ("IONS").  Under the terms of the acquisition agreeme

NEW YORK, Sept. 25, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of AKCA to Ionis for $18.15 per share in cash. If you are a AKCA investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected]. BMC Stock Holdings, Inc. (NASDAQ: BMCH) - Builders FirstSource, Inc. (NASDAQ:BLDR) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of BMCH to Builders

NEW YORK, Sept. 22, 2020 /PRNewswire/ -- Moore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders.  Moore Kuehn may ultimately seek increased consideration, additional disclosures, or other relief and benefits on behalf of the shareholders of these companies: Rosetta Stone Inc. (NYSE: RST) A solicitation statement was recently filed with the SEC regarding Cambium Learning Group's acquisition of Rosetta Stone, which may omit material information regarding the financial metrics and analyses used to evaluate the merger.  Under the propose

LONDON--(BUSINESS WIRE)--Akcea Therapeutics UK Ltd., a subsidiary of Akcea Therapeutics Inc. (NASDAQ: AKCA), announced today that the National Institute for Health and Care Excellence (NICE) has issued a positive Final Evaluation Document (FED) for volanesorsen for the treatment of Familial Chylomicronaemia Syndrome (FCS) for routine care on the National Health Service (NHS) in England. FCS is an under-recognised condition characterised by extremely high triglycerides levels (10 to 100 times normal values) and abnormal accumulation of lipoprotein particles called chylomicrons in the blood.1,2 FCS can put the patient at an increased risk of recurrent episodes of potentially fatal acu

NEW YORK, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of AIMT to Sociétés des Produits Nestlé, S.A. for $34.50 per share. If you are a AIMT investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com. Akcea Therapeutics, Inc. (NASDAQ:AKCA) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of AKCA to

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating: Rosetta Stone Inc. (NYSE: RST) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Cambium Learning Group for $30 per share. To learn more about your legal rights and options, visit: https://halpersadeh.com/actions/rosetta-stone-inc-rst-stock-merger-cambium/. Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to a consortium that includes members of Cellular Biomedicine management and several entitie